PURPOSE Tumor metastasis continues to be the major obstacle to cancer therapy and the leading cause of cancer-related death. Methods used to detect metastasis, especially occult metastases, have received a great deal attention. In this study, a novel selective peptide was assessed for its specific binding to metastasis. METHODS The FliTrx bacterial peptide display system, an alternative to ph...

Arginine-glycine-aspartic acid (RGD) peptides preferentially bind to alphavbeta3 integrin, an integrin expressed on newly formed endothelial cells and on various tumor cells. When labeled with beta-emitting radionuclides, these peptides can be used for peptide-receptor radionuclide therapy of malignant tumors. These studies aimed to investigate whether tumor targeting and tumor therapy could be...

The transcription factor signal transducer and activator of transcription (Stat) 3 is activated through the interleukin-6 family of cytokines and by binding of growth factors to the epidermal growth factor (EGF) receptor. It plays an essential role in embryonic development and assumes specialized tasks in many differentiated tissues. Constitutively activated Stat3 has been found in tumor cell l...

We previously designed a pro-cytolytic peptide to target prostate-specific membrane antigen (PSMA)-positive prostate tumor cells. The backbone of the peptide was derived from the cell lytic amoebapore H-3 domain, which becomes completely inactive upon modification by two glutamate residues linked to the ε-amide group of the COOH-terminal lysine through γ-linkages (H-3Glu2). This modified H-3 do...

Glioma-targeted drug delivery is a hugely challenging task because of the multibarrier in brain. In this study, we report magnetic T7 peptide&AS1411 aptamer-modified microemulsion for triple glioma-targeted shikonin and docetaxel (Fe3O4@T7/AS1411/DTX&SKN-M). Such system comprises two tumor-targeted ligands (T7 peptide AS1411 aptamer), ultra-small superparamagnetic iron oxide nanoparticle (Fe3O4...

We have previously conducted a phase I trial to test the efficacy of a glypican-3 (GPC3) peptide vaccine in patients with advanced hepatocellular carcinoma (HCC); however, its immunological mechanism of action remains unclear. Here, we report a pilot study conducted to evaluate the immunological mechanisms of action of this GPC3 peptide vaccine (UMIN-CTR number 000005093). Eleven patients with ...

UNLABELLED Peptides are useful tools for directing radioisotopes into tumors. We evaluated the ability of a bacterial peptide display system to isolate new prostate tumor-specific peptides. METHODS We used the bacterial FliTrx system to identify a new cyclic peptide that binds to prostate carcinoma. Serum stability and binding affinities of the (125)I-labeled peptide were tested. Furthermore,...

Abstract Cancer is the second leading cause of death worldwide after cardiovascular disease. Depending on type and location tumor, several cancer treatments are implemented. Among these, three most conventional therapies surgery, radiotherapy chemotherapy. However, there other therapeutic approaches such as photodynamic therapy (PDT). PDT relies combined action light, a photoactivable molecule ...

Low-frequency CTL and low-titer IgM responses against tumor-associated Ag MUC1 are present in cancer patients but do not prevent cancer growth. Boosting MUC1-specific immunity with vaccines, especially effector mechanisms responsible for tumor rejection, is an important goal. We studied immunogenicity, tumor rejection potential, and safety of three vaccines: 1) MUC1 peptide admixed with murine ...

Recognition of tumor-associated Ags (TAAs) on tumor cells by CTLs and the subsequent tumor cell death are assumed to be dependent on TAA protein expression and to correlate directly with the level of peptide displayed in the binding site of the HLA class I molecule. In this study we evaluated whether the levels of Her-2/neu protein expression on human tumor cell lines directly correlate with HL...